Related Experiment Video

Updated: Sep 29, 2026

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

A conjugate vaccine for the prevention of pediatric pneumococcal disease

Dennis Murray1, Cynthia Jackson

  • 1Department of Pediatrics, Medical College of Georgia, Augusta 30912-3735, USA.

Military Medicine
|August 22, 2002
PubMed

Insights

The pneumococcal 7-valent conjugate vaccine (PCV7) significantly reduces invasive pneumococcal disease in young children. This vaccine also decreases antibiotic-resistant bacteria and benefits the wider community through herd immunity.

Area of Science:

  • Pediatric infectious diseases
  • Vaccinology
  • Public health

Background:

  • Pneumococcal disease poses a significant health burden in infants and children.
  • Increasing antibiotic resistance complicates the management of pneumococcal infections.
  • Existing polysaccharide vaccines are ineffective in children under two years old.

Purpose of the Study:

  • To review the use and impact of the pneumococcal 7-valent conjugate vaccine (PCV7).
  • To assess PCV7's effectiveness in preventing pneumococcal disease in young children.
  • To evaluate PCV7's influence on antibiotic resistance and herd immunity.

Main Methods:

  • Review of existing research on PCV7 efficacy and impact.
  • Analysis of PCV7's effect on nasopharyngeal carriage of Streptococcus pneumoniae.
  • Evaluation of PCV7's role in reducing invasive pneumococcal disease incidence.

Main Results:

  • PCV7 is effective in infants and children younger than 2 years.
  • The vaccine dramatically reduces invasive pneumococcal disease incidence.
  • PCV7 decreases nasopharyngeal carriage of vaccine serotypes, including resistant strains.

Conclusions:

  • Routine PCV7 immunization is expected to substantially reduce childhood morbidity and mortality from pneumococcal disease.
  • PCV7 is anticipated to positively impact infections caused by vaccine serotypes.
  • Herd immunity and reduced antibiotic selective pressure will extend benefits beyond immunized individuals.

More Related Videos

Experimental Human Pneumococcal Carriage07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Streptococcal Pharyngitis01:27

Streptococcal Pharyngitis

Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: